These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18457319)

  • 21. Predictive value of IgG subclass levels for infectious complications in renal transplant recipients.
    Wieneke H; Otte B; Lang D; Heidenreich S
    Clin Nephrol; 1996 Jan; 45(1):22-8. PubMed ID: 8616953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thymoglobulin and its use in renal transplantation: a review.
    Thiyagarajan UM; Ponnuswamy A; Bagul A
    Am J Nephrol; 2013; 37(6):586-601. PubMed ID: 23774740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Toward individualized immunosuppression].
    Grinyó JM
    Nefrologia; 2001; 21(3):232. PubMed ID: 11471302
    [No Abstract]   [Full Text] [Related]  

  • 24. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [What is the best immunosuppression for the elderly kidney transplantation patient?].
    Ladrière M
    Nephrol Ther; 2008 Oct; 4 Suppl 3():S179-83. PubMed ID: 19000883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction therapy: why, when, and which agent?
    Krischock L; Marks SD
    Pediatr Transplant; 2010 May; 14(3):298-313. PubMed ID: 20345609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunosuppressive therapy for renal transplantation.
    Carpenter CB; Strom TB
    Springer Semin Immunopathol; 1984; 7(1):43-57. PubMed ID: 6234670
    [No Abstract]   [Full Text] [Related]  

  • 28. Lymphocyte subsets during and after rabbit anti-thymocyte globulin induction in pediatric renal transplantation: sustained T cell depletion.
    Bell L; Girardin C; Sharma A; Goodyer P; Mazer B
    Transplant Proc; 1997 Nov; 29(7A):6S-9S. PubMed ID: 9366917
    [No Abstract]   [Full Text] [Related]  

  • 29. [Current status and future perspectives of living kidney transplantation from ABO-incompatible or spousal donors].
    Tanabe K
    Nihon Geka Gakkai Zasshi; 2005 Oct; 106(10):659-62. PubMed ID: 16262153
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunosuppressive T-cell antibody induction for heart transplant recipients.
    Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
    Leichtman AB
    N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
    [No Abstract]   [Full Text] [Related]  

  • 32. Immunosuppression in older renal transplant patients.
    Morales JM; Campistol JM; Andrés A; Herrero JC
    Drugs Aging; 2000 Apr; 16(4):279-87. PubMed ID: 10874523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early rejection prophylaxis in heart transplantation: is cytolytic therapy necessary?
    Renlund DG; O'Connell JB; Bristow MR
    J Heart Transplant; 1989; 8(3):191-3. PubMed ID: 2661767
    [No Abstract]   [Full Text] [Related]  

  • 34. [Immunosuppressive treatments: mechanisms of action and clinical use].
    Thervet E; Zuber J; Sberro R; Canaud G; Anglicheau D; Snanoudj R; Mamzer-Bruneel MF; Martinez F; Legendre C
    Nephrol Ther; 2011 Dec; 7(7):566-81. PubMed ID: 21273149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Polyomavirus and tubulointerstitial nephropathy].
    Antoine C; Hill G; Glotz D; Fontanière B; Tabone E; Nochy D
    Nephrologie; 2001; 22(6):317-20. PubMed ID: 11715610
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The need for minimization strategies: current problems of immunosuppression.
    Bamoulid J; Staeck O; Halleck F; Khadzhynov D; Brakemeier S; Dürr M; Budde K
    Transpl Int; 2015 Aug; 28(8):891-900. PubMed ID: 25752992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current possibilities and trends in biological immunosuppression in transplantation of organs and tissues. II].
    Păuşescu E
    Microbiol Parazitol Epidemiol (Bucur); 1973; 18(6):519-26. PubMed ID: 4597674
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects.
    Bamoulid J; Staeck O; Crépin T; Halleck F; Saas P; Brakemeier S; Ducloux D; Budde K
    Nephrol Dial Transplant; 2017 Oct; 32(10):1601-1608. PubMed ID: 27798202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of daclizumab to ATGAM induction in simultaneous pancreas-kidney transplant recipients on triple maintenance immunosuppression.
    Rasaiah SB; Light JA; Sasaki TM; Currier CB
    Clin Transplant; 2000 Aug; 14(4 Pt 2):409-12. PubMed ID: 10946780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.